
    
      This Phase II randomized, double-blind, placebo-controlled, study will assess 2 different
      doses of GLS-1027 in the prevention of severe pneumonitis among those hospitalized with PCR
      confirmed SARS-CoV-2 infection. Subjects will be randomized at a 1:1:1 ratio to either
      Standard of Care (SOC) plus placebo, or SOC plus GLS-1027 at either 120 mg or 360 mg daily.
      Clinical status will be monitored through 56 days from the initiation of treatment.
    
  